Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7261 to 7275 of 7964 results

  1. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued [GID-TA10228]

  2. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued [GID-TA10233]

  3. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued [GID-TA10234]

  4. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued [GID-TA10236]

  5. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued [GID-TA10242]

  6. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued [GID-TA10243]

  7. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued [GID-TA10244]

  8. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued [GID-TA10254]

  9. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued [GID-TA10259]

  10. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued [GID-TA10267]

  11. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued [GID-TA10271]

  12. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued [GID-TA10277]

  13. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued [GID-TA10284]